Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Ibrutinib, Obinutuzumab, and Venetoclax in CLL
NCT03755947Phase 2Completed
- Sponsor
- PETHEMA
- Start
- Dec 2018
- Primary completion
- Dec 2020
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib, obinutuzumab, venetoclax in chronic lymphocytic leukemia (CLL), sponsored by PETHEMA. Started Dec 2018; status: completed.
02
Drugs
ibrutinibobinutuzumabvenetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03755947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03755947.